ImmunityBio Investors Alert for Class Action Lawsuit
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 06 2026
0mins
Should l Buy IBRX?
Source: Globenewswire
- Lawsuit Deadline: Investors must file Lead Plaintiff applications by May 26, 2026, if they purchased ImmunityBio securities between January 19 and March 24, 2026, indicating significant legal risks that could impact the company's stock performance.
- FDA Warning Impact: Following a March 13, 2026 FDA warning letter accusing ImmunityBio of false advertising regarding Anktiva, the company's stock plummeted 21% on March 24, 2026, reflecting market concerns over compliance and credibility.
- Legal Liability Allegations: ImmunityBio and certain executives are charged with failing to disclose material information during the class period, violating federal securities laws, which could lead to substantial financial repercussions for the company and its investors.
- Investor Rights Protection: Kahn Swick & Foti LLC encourages affected investors to consult via phone or email regarding their rights, highlighting the firm's commitment to safeguarding investor interests, which may influence future litigation strategies.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy IBRX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on IBRX
Wall Street analysts forecast IBRX stock price to fall
3 Analyst Rating
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 8.000
Low
5.00
Averages
7.33
High
9.00
Current: 8.000
Low
5.00
Averages
7.33
High
9.00
About IBRX
Immunitybio, Inc. is a vertically integrated, clinical-stage biotechnology company developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Using its applied science and platforms to treat cancers, including the development of potential cancer vaccines, as well as developing immunotherapies and cell therapies to reduce or eliminate the need for standard high-dose chemotherapy. Its platforms and their associated product candidates are designed to attack cancer and infectious pathogens by activating both the innate immune system, including NK cells, dendritic cells, and macrophages, as well as the adaptive immune system comprising B and T cells, in an orchestrated manner. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins, vaccine vectors, and cell therapies. Its biologic commercial product candidate, Anktiva, is an IL-15 superagonist antibody-cytokine fusion protein.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
ImmunityBio Seeks ANKTIVA Label Expansion for NMIBC
- FDA Review Progress: The U.S. FDA has accepted ImmunityBio's supplemental Biologics License Application (sBLA) for ANKTIVA, aiming to expand its indication to include patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC), with a decision expected by January 6, 2027, which could significantly increase treatment options.
- Clinical Data Support: The sBLA submission is based on data from the QUILT-3.032 trial, showing a 12-month disease-free survival rate of 58.2% in 80 high-risk patients treated with ANKTIVA plus BCG, providing scientific justification for the indication expansion that may improve patient outcomes.
- Expert Consensus Reinforcement: At the FDA workshop in May 2026, experts unanimously agreed that CIS and papillary disease are biologically the same, supporting the inclusion of papillary disease in existing treatment protocols, highlighting the urgent treatment needs for BCG-unresponsive patients and furthering the sBLA review.
- Significant Market Potential: The expanded indication for ANKTIVA positions it as a crucial immunotherapy option for BCG-unresponsive patients, likely enhancing ImmunityBio's competitiveness in the bladder cancer treatment market and addressing the urgent needs of approximately 64,000 NMIBC patients diagnosed annually.
See More
U.S. Stock Futures Mixed Amid Rising Inflation Concerns
- Futures Market Movement: As of 10 p.m. ET, Nasdaq 100 futures rose by 0.20% and S&P 500 futures increased by 0.06%, while Dow Jones futures remained flat, indicating cautious optimism ahead of Nvidia's quarterly results.
- Rising Bond Yields: The yield on 10-year U.S. Treasury notes climbed for the third consecutive day to 4.675%, the highest since January 2025, while the 30-year yield breached 2007 levels at around 5.20%, intensifying inflation concerns in the market.
- Tech Stock Pullback: Amid a broad decline in technology stocks, the Nasdaq Composite fell by 220 points, closing down 0.84%, with most of the
See More
ImmunityBio Investors Alert for Class Action Lawsuit
- Lawsuit Notification: Investors in ImmunityBio are reminded that those who purchased the company's securities between January 19, 2026, and March 24, 2026, must file lead plaintiff applications by May 26, 2026, to participate in the class action lawsuit against the company.
- FDA Warning Impact: Following a warning letter from the FDA regarding misleading cancer therapy advertisements, ImmunityBio's stock price plummeted by 21% on March 24, 2026, resulting in a loss of $1.98 per share, indicating significant market concerns over the company's compliance.
- Legal Accountability: The lawsuit alleges that ImmunityBio and certain executives failed to disclose material information during the class period, violating federal securities laws, which could expose investors to greater economic losses.
- Legal Consultation Opportunity: Investors seeking to understand their legal rights and the potential impact of this case on their economic losses can contact Kahn Swick & Foti law firm for obligation-free legal consultation services.
See More
FDA Reviews Anktiva Expansion Application for Bladder Cancer
- FDA Review Progress: The FDA has accepted ImmunityBio's application to expand the use of Anktiva plus BCG for bladder cancer, with a final decision expected by January 6, 2027, marking a significant turnaround from last year's refusal and potentially opening new market opportunities for the company.
- Patient Population Impact: The application targets patients with papillary-only bladder cancer, which ImmunityBio claims accounts for 85% of the 64,000 new non-muscle invasive bladder cancer cases diagnosed annually in the U.S., and a successful expansion could significantly enhance its market share in bladder cancer treatment.
- Clinical Research Support: ImmunityBio's Quilt-3.032 study demonstrated that 58.2% of high-risk patients treated with Anktiva plus BCG remained disease-free after 12 months, and over 80% avoided bladder removal surgery within three years, showcasing the treatment's effectiveness and safety.
- Global Expansion Strategy: Despite facing regulatory challenges from the FDA, ImmunityBio is aggressively expanding Anktiva's supply chain globally, recently signing an exclusive agreement with Japan BCG Laboratory to secure a second supply source amid chronic U.S. shortages, further solidifying its market position.
See More
ImmunityBio's Anktiva Plus BCG Shows Significant Advantages in Bladder Cancer Treatment
- Efficacy Comparison: Anktiva combined with BCG demonstrated a median duration of complete response of 22.1 months in patients with BCG-unresponsive non-muscle invasive bladder cancer, significantly surpassing Nadofaragene's 9.7 months, indicating a potential shift in treatment standards.
- Reduced Side Effects: Patients treated with Anktiva plus BCG experienced a 68% lower risk of treatment-related adverse events compared to TAR-200, which may enhance patient compliance and quality of life due to fewer side effects.
- Enhanced Patent Protection: ImmunityBio secured five U.S. patents covering the use of Anktiva in combination with BCG, with protection lasting until 2035, providing a stronger competitive barrier and market position in bladder cancer treatment.
- Positive Market Sentiment: Despite IBRX shares trading 7% lower, retail sentiment on Stocktwits remains 'bullish', with users expressing that the stock being under $8 is 'incredible', reflecting optimistic expectations regarding the newly released data.
See More
GT Biopharma Advances NK Cell Immunotherapy with TriKE Candidates
- Clinical Advancement: GT Biopharma has advanced three TriKE candidates into the clinic, with GTB-5550 dosing initiated on May 14, 2026, marking a significant milestone in NK cell therapy that is expected to enhance its market competitiveness.
- Innovative Platform: The company's second-generation TriKE platform is described as 10-40 times more potent than the first generation, focusing on activating NK cells through nanobody technology, thereby improving therapeutic efficacy and reducing side effects, further solidifying its position in immuno-oncology.
- Funding Influx: Cumulative funding into NK-focused biotech has exceeded $4.2 billion from 2020 to 2026, indicating strong investment enthusiasm and market potential, with GT Biopharma positioned to benefit from this trend as a key player.
- Market Outlook: North America is expected to capture 44% of the global NK cell therapy market by 2026, and GT Biopharma's clinical trials and financial status provide a solid foundation for growth in this rapidly evolving market.
See More
ImmunityBio Seeks ANKTIVA Label Expansion for NMIBC
- FDA Review Progress: The U.S. FDA has accepted ImmunityBio's supplemental Biologics License Application (sBLA) for ANKTIVA, aiming to expand its indication to include patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC), with a decision expected by January 6, 2027, which could significantly increase treatment options.
- Clinical Data Support: The sBLA submission is based on data from the QUILT-3.032 trial, showing a 12-month disease-free survival rate of 58.2% in 80 high-risk patients treated with ANKTIVA plus BCG, providing scientific justification for the indication expansion that may improve patient outcomes.
- Expert Consensus Reinforcement: At the FDA workshop in May 2026, experts unanimously agreed that CIS and papillary disease are biologically the same, supporting the inclusion of papillary disease in existing treatment protocols, highlighting the urgent treatment needs for BCG-unresponsive patients and furthering the sBLA review.
- Significant Market Potential: The expanded indication for ANKTIVA positions it as a crucial immunotherapy option for BCG-unresponsive patients, likely enhancing ImmunityBio's competitiveness in the bladder cancer treatment market and addressing the urgent needs of approximately 64,000 NMIBC patients diagnosed annually.
See More
U.S. Stock Futures Mixed Amid Rising Inflation Concerns
- Futures Market Movement: As of 10 p.m. ET, Nasdaq 100 futures rose by 0.20% and S&P 500 futures increased by 0.06%, while Dow Jones futures remained flat, indicating cautious optimism ahead of Nvidia's quarterly results.
- Rising Bond Yields: The yield on 10-year U.S. Treasury notes climbed for the third consecutive day to 4.675%, the highest since January 2025, while the 30-year yield breached 2007 levels at around 5.20%, intensifying inflation concerns in the market.
- Tech Stock Pullback: Amid a broad decline in technology stocks, the Nasdaq Composite fell by 220 points, closing down 0.84%, with most of the
See More
ImmunityBio Investors Alert for Class Action Lawsuit
- Lawsuit Notification: Investors in ImmunityBio are reminded that those who purchased the company's securities between January 19, 2026, and March 24, 2026, must file lead plaintiff applications by May 26, 2026, to participate in the class action lawsuit against the company.
- FDA Warning Impact: Following a warning letter from the FDA regarding misleading cancer therapy advertisements, ImmunityBio's stock price plummeted by 21% on March 24, 2026, resulting in a loss of $1.98 per share, indicating significant market concerns over the company's compliance.
- Legal Accountability: The lawsuit alleges that ImmunityBio and certain executives failed to disclose material information during the class period, violating federal securities laws, which could expose investors to greater economic losses.
- Legal Consultation Opportunity: Investors seeking to understand their legal rights and the potential impact of this case on their economic losses can contact Kahn Swick & Foti law firm for obligation-free legal consultation services.
See More
FDA Reviews Anktiva Expansion Application for Bladder Cancer
- FDA Review Progress: The FDA has accepted ImmunityBio's application to expand the use of Anktiva plus BCG for bladder cancer, with a final decision expected by January 6, 2027, marking a significant turnaround from last year's refusal and potentially opening new market opportunities for the company.
- Patient Population Impact: The application targets patients with papillary-only bladder cancer, which ImmunityBio claims accounts for 85% of the 64,000 new non-muscle invasive bladder cancer cases diagnosed annually in the U.S., and a successful expansion could significantly enhance its market share in bladder cancer treatment.
- Clinical Research Support: ImmunityBio's Quilt-3.032 study demonstrated that 58.2% of high-risk patients treated with Anktiva plus BCG remained disease-free after 12 months, and over 80% avoided bladder removal surgery within three years, showcasing the treatment's effectiveness and safety.
- Global Expansion Strategy: Despite facing regulatory challenges from the FDA, ImmunityBio is aggressively expanding Anktiva's supply chain globally, recently signing an exclusive agreement with Japan BCG Laboratory to secure a second supply source amid chronic U.S. shortages, further solidifying its market position.
See More
ImmunityBio's Anktiva Plus BCG Shows Significant Advantages in Bladder Cancer Treatment
- Efficacy Comparison: Anktiva combined with BCG demonstrated a median duration of complete response of 22.1 months in patients with BCG-unresponsive non-muscle invasive bladder cancer, significantly surpassing Nadofaragene's 9.7 months, indicating a potential shift in treatment standards.
- Reduced Side Effects: Patients treated with Anktiva plus BCG experienced a 68% lower risk of treatment-related adverse events compared to TAR-200, which may enhance patient compliance and quality of life due to fewer side effects.
- Enhanced Patent Protection: ImmunityBio secured five U.S. patents covering the use of Anktiva in combination with BCG, with protection lasting until 2035, providing a stronger competitive barrier and market position in bladder cancer treatment.
- Positive Market Sentiment: Despite IBRX shares trading 7% lower, retail sentiment on Stocktwits remains 'bullish', with users expressing that the stock being under $8 is 'incredible', reflecting optimistic expectations regarding the newly released data.
See More
GT Biopharma Advances NK Cell Immunotherapy with TriKE Candidates
- Clinical Advancement: GT Biopharma has advanced three TriKE candidates into the clinic, with GTB-5550 dosing initiated on May 14, 2026, marking a significant milestone in NK cell therapy that is expected to enhance its market competitiveness.
- Innovative Platform: The company's second-generation TriKE platform is described as 10-40 times more potent than the first generation, focusing on activating NK cells through nanobody technology, thereby improving therapeutic efficacy and reducing side effects, further solidifying its position in immuno-oncology.
- Funding Influx: Cumulative funding into NK-focused biotech has exceeded $4.2 billion from 2020 to 2026, indicating strong investment enthusiasm and market potential, with GT Biopharma positioned to benefit from this trend as a key player.
- Market Outlook: North America is expected to capture 44% of the global NK cell therapy market by 2026, and GT Biopharma's clinical trials and financial status provide a solid foundation for growth in this rapidly evolving market.
See More
